@Article{096504018X15313896322888,
AUTHOR = {Yaohong Liu, Wensou Huang, Mingji He, Hui Lian, Yongjian Guo, Jingjun Huang, Jingwen Zhou, Kangshun Zhu},
TITLE = {Efficacy and Safety of CalliSpheres<sup>®</sup> Drug-Eluting Beads Transarterial  Chemoembolization in Barcelona Clinic Liver Cancer Stage C Patients},
JOURNAL = {Oncology Research},
VOLUME = {27},
YEAR = {2019},
NUMBER = {5},
PAGES = {565--573},
URL = {http://www.techscience.com/or/v27n5/48572},
ISSN = {1555-3906},
ABSTRACT = {This study aimed to investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization 
(DEB-TACE) treatment in Barcelona Clinic Liver Cancer (BCLC) stage C liver cancer patients. In 39 patients 
with BCLC stage C liver cancer, after the first cycle of DEB-TACE, 2 (5.1%) and 24 (61.5%) patients achieved 
complete response (CR) and partial response (PR) to give an overall objective response rate (ORR) of 66.7%. 
With respect to the second cycle of therapy, the ORR was higher in patients receiving DEB-TACE compared 
with those receiving cTACE (57.1% vs. 11.1%). After the first cycle of DEB-TACE treatment, the percentages 
of abnormal albumin (ALB), total protein (TP), total bilirubin (TBIL), and alanine aminotransferase (ALT) 
worsened at 1 week and recovered at 1 month. The number of patients with abnormal aspartate aminotransferase (AST) did not increase at 1 week but elevated at 1 month. After the second cycle of DEB-TACE or 
cTACE treatment, no difference was observed between cTACE and DEB-TACE in terms of all adverse events 
(AEs) at all visits, and most of the AEs did not change after the second cycle in both groups. The most common 
AEs after the first and second treatment cycles were pain, fever, and nausea/vomiting. These results demonstrate that DEB-TACE offers patients with BCLC stage C liver cancer a clinically active short-term treatment 
that is safe and relatively well tolerated.},
DOI = {10.3727/096504018X15313896322888}
}